A greater understanding of the biology of mesothelioma has led to new clinical trials testing immunotherapies and targeted drugs against the disease.
Cancer Research UK and Biotecnol Limited will trial an experimental immuno-oncology treatment for some patients with advanced tumours.
An exciting new partnership will see a combination of drugs tested in mesothelioma, lung and pancreatic cancers for the first time.
Suppressing the body's natural defences could improve how well mesothelioma patients respond to certain treatments, a US study suggests.
Cancer Research UK has contacted the health secretary to ask that Nice, the UK drugs regulator, reconsider its decision not to make the lung cancer drug Alimta available...
A vaccine against mesothelioma, a cancer associated with exposure to asbestos, has shown early promise in its first clinical trial.